Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Organon, the healthcare business unit of Akzo Nobel, has signed a worldwide license agreement with Endotis Pharma concerning the development and commercialization of several antithrombotic compounds. Financial details have not been disclosed.
Subscribe to our email newsletter
Under the terms of the agreement, Endotis has acquired exclusive rights to develop and commercialize Org 42675, Org 217609 (a neutralizable follow-up of Org 42675) and Org 224283, three antithrombotic compounds with an innovative dual mechanism of action.
Charles Woler, chairman and CEO of Endotis Pharma, said: “We are delighted to sign this licensing agreement, as these compounds will strongly reinforce our position in thrombosis. Due to their oligosaccharide structure, they perfectly fit with our focus on small-glyco drugs. We are proud that Organon has faith in Endotis to develop these very promising compounds.”
David Nicholson, executive vice president R&D of Organon, said: “We are excited to bring this opportunity to Endotis. Organon will continue to be involved bringing in our expertise in manufacturing and development. This deal maximizes the chances of bringing these innovative compounds to patients in need of anti-thrombotic care.”